Prime Medicine

Gene editing technology for genetic diseases

Cambridge, Massachusetts, United States

About Prime Medicine

Prime Medicine focuses on gene editing, specifically using a technology called Prime Editing to make precise changes to DNA. This technology can identify and fix faulty DNA segments, which helps restore normal genetic function. The company aims to cure, halt, or prevent genetic diseases, providing long-term benefits to patients. Prime Medicine targets individuals with genetic disorders, a significant market globally. Unlike many competitors, it emphasizes collaboration with research institutions and pharmaceutical companies to advance its technology and bring it to market through licensing agreements and partnerships. The leadership team has extensive experience in developing innovative medicines, and the company is committed to enhancing its technological capabilities.

Cambridge, MassachusettsHeadquarters
2019Year Founded
$306.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Flexible Work Hours

Risks

Intellectual property disputes may lead to costly legal battles and delays.
The competitive landscape in gene editing is intensifying, challenging Prime Medicine's market position.
Reliance on partnerships exposes Prime Medicine to risks if collaborations don't meet expectations.

Differentiation

Prime Editing offers precise DNA modifications without double-stranded breaks, unlike CRISPR.
Prime Medicine's technology can correct faulty DNA segments, restoring normal genetic function.
The company collaborates with top-tier partners like Bristol Myers Squibb for strategic growth.

Upsides

Prime Medicine secured $244.6M to advance its genetic therapies and pipeline.
The partnership with Bristol Myers Squibb includes potential milestone payments over $3.5 billion.
Growing interest in gene editing for rare diseases boosts investment and collaboration opportunities.

Funding

Total raised$306.41 M
Latest valuation$1.20 B
StageIPO
POST IPO EQUITY
2/29/2024
$161
IPO
9/30/2022
$175
$200
$1.20 B